Scott M. Lassman will be participating in a panel discussion on June 19, 2020 on Hot Topics in Drug and Medical Device Regulation, which is part of Washington College of Law's Virtual Summer Series on Health Law and Policy (co-sponsored by the American Health Law Association). He will be presenting on new developments regarding orphan drug exclusivity.

Chambers USA recently recognized Scott M. Lassman as a leading attorney (Band 2) in the category of Healthcare: Pharmaceutical/Medical Products Regulatory. Chambers USA specifically highlighted his ability to provide practical solutions to complex regulatory issues, his efficiency, and his "deep knowledge of Hatch-Waxman."

Scott M. Lassman is scheduled to speak about New, Emerging, and Continually Interesting Issues at the Food and Drug Law Institute's Introduction to Biologics and Biosimilars Law and Regulation conference on April 1, 2020.

Scott M. Lassman was recently recognized by Who's Who Legal as a recommended regulatory attorney in its Life Sciences 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

On February 27, 2020, Scott M. Lassman presented a webinar on recent developments affecting exclusivity for drugs and biological products. The webinar was hosted by FDANews.

Scott M. Lassman recently was recognized as a leading regulatory attorney in the Who's Who Legal Healthcare 2020 guide.

The Who's Who Legal research process is based on recommendations and feedback from eminent private practitioners in the sector as well as from corporate counsel.

Scott M. Lassman participated in a panel discussion entitled Biosimilars at the Bar at AAM's GRx+Biosims Conference on November 4, 2019. The panel discussed recent legal developments affecting biosimilars, including interchangeability, labeling carve-outs, enhancements to the Purple Book and regulatory pathways for approval of "biobetters."

Scott M. Lassman recently was recognized by LMG Life Sciences as a Regulatory Law Star in the areas of pharmaceutical and medical device regulatory law for 2019.

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.